Scarica l'app Stockscreener
0.4988
4.08%
-0.0212
Dopo l'orario di chiusura:
.51
0.0112
+2.25%
Precedente Chiudi:
$0.52
Aprire:
$0.5095
Volume 24 ore:
2.12M
Relative Volume:
0.72
Capitalizzazione di mercato:
$81.10M
Reddito:
-
Utile/perdita netta:
$-111.13M
Rapporto P/E:
-0.3779
EPS:
-1.32
Flusso di cassa netto:
$-91.53M
1 W Prestazione:
-22.35%
1M Prestazione:
+13.36%
6M Prestazione:
-71.82%
1 anno Prestazione:
-89.11%
Intervallo 1D:
$0.4834
$0.5196
Intervallo di 1 settimana:
$0.4834
$0.65
Portata 52W:
$0.4054
$4.96
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Nome
Tenaya Therapeutics Inc
Settore
Industria
Telefono
415-865-2066
Indirizzo
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Confronta TNYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.4988 | 81.10M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-10 | Iniziato | William Blair | Outperform |
| 2023-11-30 | Iniziato | Leerink Partners | Outperform |
| 2022-06-15 | Iniziato | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Borsa (TNYA) Ultime notizie
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Tenaya to lay off about one-third of staff, reveals heart gene therapy data - Endpoints News
Top 3 Insider Stock Buys in March-Are They Still Good in April? - MSN
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting - GlobeNewswire
Revolutionary Gene Therapy Transforms Severe Heart Disease Patients in Landmark Trial - Stock Titan
Undervalued Cardiology Stocks to Watch: TNYA, MIST, BBIO, ALNY - GuruFocus
Tenaya Therapeutics IncOn Mar 27, Co Approves Restructuring PlanSEC Filing - MarketScreener
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - MSN
FY2025 Earnings Estimate for TNYA Issued By Chardan Capital - Defense World
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance
Top 3 Insider Stock Buys in March—Are They Still Good in April? - Benzinga
Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function - Yahoo Finance
Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - simplywall.st
Tenaya reports promising gene therapy for heart condition By Investing.com - Investing.com South Africa
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial - MarketScreener
Tenaya reports promising gene therapy for heart condition - Investing.com India
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo Finance
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models - GlobeNewswire
Revolutionary Heart Disease Treatment: Gene Therapy Reverses Cardiac Damage in Landmark Study - Stock Titan
Tenaya Therapeutics announces $300M mixed shelf offering; shares down - MSN
Tenaya Therapeutics files for mixed shelf offering of up to $300 mln -March 21, 2025 at 04:16 pm EDT - MarketScreener
Tenaya Therapeutics to Present New Data on MYBPC3-Associated Hypertrophic Cardiomyopathy at ACC 2025 Annual Scientific Session - Nasdaq
Tenaya Therapeutics Announces Late Breaker and New Data - GlobeNewswire
Major Breakthrough: Tenaya's Gene Therapy Trial Reveals Critical One-Year Heart Disease Data - StockTitan
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Canaccord Genuity Group Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $6.00 - Defense World
Analysts Issue Forecasts for TNYA Q1 Earnings - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Morgan Stanley Has Lowered Expectations for Tenaya Therapeutics (NASDAQ:TNYA) Stock Price - Defense World
Chardan Capital Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $9.00 - Defense World
What is HC Wainwright’s Estimate for TNYA Q1 Earnings? - Defense World
Canaccord cuts Tenaya Therapeutics price target to $6 By Investing.com - Investing.com South Africa
Canaccord cuts Tenaya Therapeutics price target to $6 - Investing.com
Q1 Earnings Forecast for TNYA Issued By Lifesci Capital - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Chardan Adjusts Price Target on Tenaya Therapeutics to $9 From $18, Keeps Buy Rating - Marketscreener.com
H.C. Wainwright cuts Tenaya Therapeutics price target to $5 By Investing.com - Investing.com Canada
Tenaya Therapeutics Advances Gene Therapy Pipeline - TipRanks
H.C. Wainwright cuts Tenaya Therapeutics price target to $5 - Investing.com
Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.
Tenaya Therapeutics SVP sells shares worth $1,334 By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 By Investing.com - Investing.com Australia
Tenaya Therapeutics chief medical officer sells shares worth $3,982 By Investing.com - Investing.com South Africa
Tenaya Therapeutics chief medical officer sells shares worth $3,982 - Investing.com India
Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 - Investing.com India
Tenaya Therapeutics Inc Azioni (TNYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):